Endocan, VEGF and TNF-alpha Levels in Periodontal Disease and After Treatment

Effect of Non-surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Endocan, Vascular Endothelial Growth Factor-A and Tumor Necrosis Factor Alpha Levels

The primer aim of the study was to determine serum and gingival crevicular fluid (GCF) endocan levels in periodontal diseases pathogenesis supported with vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α) levels.

The study consist of three groups: periodontally healthy individuals (group 1; n = 20), individuals with generalized chronic periodontitis (group 2; n = 20), the same patients with chronic periodontitis after they had been treated with scaling and root planing (SRP) were considered as Group 3. Clinical measurements were recorded; GCF and serum samples were obtained from each participant before and 6 weeks after therapy. Endocan, VEGF-A and TNF-α levels were measured by enzyme-linked immunosorbent assay.

Group 1 Inclusion Criteria:

• No bone and attachment loss,
• GI=0, PPD≤3mm, CAL≤3mm
• Systematically healthy patients

Group 2 Inclusion Criteria:

• GI>1, PPD≥5mm, CAL≥5mm with alveolar bone loss radiographically.
• Systematically healthy patients

Exclusion Criteria:

• Aggressive Periodontitis,
• Oral pathologies,
• Patients with any other systemic diseases,
• Pregnant women and those in the lactation period,
• Patients with smoking habit and taking medication
• Patients received periodontal therapy in last 6 months